Edwards Lifesciences Corporation (ETR:EWL)
Germany · Delayed Price · Currency is EUR | Market Cap | 43.21B +8.5% |
| Revenue (ttm) | 5.47B +14.1% |
| Net Income | 950.73M -73.8% |
| EPS | 1.63 -73.2% |
| Shares Out | n/a |
| PE Ratio | 45.45 |
| Forward PE | 28.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 74.56 |
| Previous Close | 75.08 |
| Day's Range | 74.56 - 75.90 |
| 52-Week Range | 62.00 - 76.94 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 23, 2026 |
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aor... [Read more]
Financial Performance
In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.
Financial numbers in USD Financial StatementsNews
Pacific Defense Launches Dual-Enclave 100G Ethernet Switch for Secure Multi-Mission C5ISR and Electronic Warfare Systems
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense today announced the launch of the SWH1530VP, a next-generation dual-enclave 100/40 Gigabit Ethernet switch engineered to provide secure, determinis...
Leerink ‘incrementally positive’ on Edwards Lifesciences after TAVR NCD proposal
Leerink analyst Mike Kratky is incrementally positive on Edwards Lifesciences (EW) following the release of the transcatheter aortic valve replacement national coverage determination proposed decision...
TAVR NCD proposal ‘uber bullish’ for Edwards Lifesciences, says Evercore ISI
After CMS released its updated TAVR national coverage proposal, which now incorporates coverage for asymptomatic severe aortic stenosis, Evercore ISI calls this “an uber bullish scenario” for Edwards ...
Edwards Lifesciences up 3% to $89 after CMS coverage proposal for TAVR
08:38 EDT Edwards Lifesciences (EW) up 3% to $89 after CMS coverage proposal for TAVR
East West Announces $858,000 Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - East West Minerals Ltd. (TSXV: EW) ("East West" or the "Company") announces that further to a price reservation filed on June 10, 2026, ...
Edwards Lifesciences price target raised to $104 from $97 at TD Cowen
TD Cowen analyst Joshua Jennings raised the firm’s price target on Edwards Lifesciences (EW) to $104 from $97 and keeps a Buy rating on the shares. The firm said it…
Edwards Lifesciences Transcript: Bank of America Global Healthcare Conference 2026
Strong Q1 results and increased guidance reflect broad-based growth in TAVR, surgical, and TMTT segments, supported by new clinical evidence and product innovation. Leadership changes and a robust pipeline position the company for sustained double-digit growth and margin improvement through 2027 and beyond.
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) a...
Edwards Lifesciences appoints Theodora Mistras as CFO
Edwards Lifesciences (EW) announced the appointment of Theodora Mistras as the company’s corporate vice president and CFO, effective at the end of May. Mistras will succeed Scott Ullem, who announced…
Edwards Lifesciences Announces Appointment of CFO
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company's corporate vice president and chief financial officer (...
Edwards Lifesciences announces 10-year results from Commence aortic trial
Edwards Lifesciences (EW) announced 10-year results from the Commence aortic trial, reinforcing the long-term durability and sustained performance of its proprietary Resilia tissue. The data were pres...
Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its propriet...
Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chi...
Edwards Lifesciences price target raised to $110 from $104 at Barclays
Barclays raised the firm’s price target on Edwards Lifesciences (EW) to $110 from $104 and keeps an Overweight rating on the shares following the Q1 report. The company’s quarter showed…
Edwards Lifesciences price target raised to $90 from $89 at Truist
Truist raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $89 and keeps a Hold rating on the shares. The firm is citing the company’s clean earnings…
Edwards Lifesciences price target raised to $93 from $92 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Edwards Lifesciences (EW) to $93 from $92 and keeps an Outperform rating on the shares.
Edwards Lifesciences price target raised to $100 from $98 at BTIG
BTIG raised the firm’s price target on Edwards Lifesciences (EW) to $100 from $98 and keeps a Buy rating on the shares. The firm is citing the company’s better-than-expected Q1…
Edwards Lifesciences price target lowered to $85 from $87 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on Edwards Lifesciences (EW) to $85 from $87 and keeps a Hold rating on the shares. The firm noted management raised…
Edwards Lifesciences price target raised to $87 from $85 at Baird
Baird analyst David Rescott raised the firm’s price target on Edwards Lifesciences (EW) to $87 from $85 and keeps a Neutral rating on the shares. The firm updated its model…
Edwards Lifesciences price target lowered to $100 from $103 at BofA
BofA analyst Travis Steed lowered the firm’s price target on Edwards Lifesciences (EW) to $100 from $103 and keeps a Buy rating on the shares. Q1 came in well above…
Edwards Lifesciences beats quarterly estimates on robust demand for artificial heart valves
Edwards Lifesciences beat Wall Street first-quarter estimates on Thursday, driven by robust demand for its artificial valves used in complex cardiac procedures, sending its shares up over 4% in exte...
Edwards Lifesciences Earnings Call Transcript: Q1 2026
Q1 2026 saw 12.7% sales growth, driven by strong TAVR, TMTT, and Surgical performance, prompting raised full-year guidance for sales and EPS. Robust clinical evidence, innovation, and favorable market dynamics support continued growth across all segments.
Edwards Lifesciences Earnings release: Q1 2026
Edwards Lifesciences released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Edwards Lifesciences Quarterly report: Q1 2026
Edwards Lifesciences has published its Q1 2026 quarterly earnings report on April 23, 2026.
Edwards Lifesciences sees Q2 EPS 70c-76c, consensus 75c
Sees Q2 revenue $1.66B-$1.74B, consensus $1.68B